219 results about "Functional disability" patented technology

The present invention relates to methods and compositions for reducing Distress Dysfunction by restoring and maintaining homeostatic balance in the neurotransmitter systems underlying the Stress Response and the experience of distress and hedonic tone. Distress Dysfunction refers to the experience of dysfunctional emotional and physical distress that interferes with the individual's quality of life and functioning. A novel understanding of the bimodal opioid modulation of pain, and its impact, through serotonergic, dopaminergic, epinephrinergic, and norepinephrinergic processes, on hedonic tone, leads directly to new generation pharmaceutical formulations that are remarkably safe and effective for the treatment of a wide variety of Distress Dysfunctions, including anxiety, depression, anger, insomnia, mood disorders, eating disorders, sexual problems, pain, substance and behavioral addictions, gastrointestinal disorders, autistic spectrum disorders, attention-deficit and hyperactivity disorders, and other emotional and physical distress disorders. The foundation of this discovery is the power of Receptor Switchers, such as ultra-low-dose and very-low-dose opioid antagonists and GM1 ganglioside attenuators, in blocking acute and protracted excitatory opioid receptor signaling. Co-administration of Receptor Switchers with Endorphin Enhancers, such as specific cAMP PDE inhibitors and excitatory amino acids, is an excellent formulation for restoring healthy homeostatic balance to the endogenous opioid system, using the body's endorphins to reduce emotional and physical distress, and through synergistic and homeostatic processes, restoring positive hedonic tone. The addition of Synergistic Enhancers, such as amino acids, SSRI and SNRI agents, and non-opioid analgesics, as well as Exogenous Opioids, enhances and prolongs these therapeutic benefits. The novel principles discovered by this invention also teach a new generation of safe and effective formulations for the treatment of respiratory conditions, neuropathy, and nociceptive pain.

A system and method for instant and permanent pain relief on pain-spasm-pain neurological reflex cycles that cause pain and functional disability in muscles suffering from acute and chronic soft tissue disorders is disclosed. The invention comprises a device for diagnosing PSP (pain-spasm-pain) cycles by creating a calibrated mechanical stimulation on the Golgi Tendon (GT) receptors of related muscle fibres, over which pain relief is later on provided by simultaneously applying calibrated pressure on said GT receptors. The system involves diagnosis and treatment steps performed instantly, in consequence of which the muscles permanently retain their normal physiological and mechanical values. The system proposed by the invention is characterized by a stimulator tip which is used to apply mechanical pressure the golgi tendon receptors beneath the skin, and which is attached to said tensiometric instrument (8) used for measuring the GT pain pressure thresholds and GT inhibition pressure thresholds.

The invention relates to an automatic discrimination analysis method of mild cognitive impairment based on a support vector machine. According to the automatic discrimination analysis method of mild cognitive impairment based on the support vector machine, multiple detection index data including aresting state fMRI, structure MRI and neuropsychological examination data are used, and methods of Functional Connectivity (FC) analysis, Voxel-based Morphometry (VBM) analysis and Fiber Tractography are adopted to extract a resting state functional connectivity characteristic, a gray matter structure characteristic and a white matter fiber connectivity characteristic, reduction is conducted on the characteristics based on a rough set approach, and finally classifier construction is conducted on multimodal MRI data based on the SVM method, so that automatic discrimination analysis of mild cognitive impairment is achieved, diagnosis accuracy of mild cognitive impairment is improved, and the accuracy rate of the diagnosis in experimental data reaches more than 90 percent. The method can be applied to practical clinical diagnosis.

The invention provides a traditional Chinese medicine composition for improving memory and mild cognitive impairment. The traditional Chinese medicine composition comprises 40-80 parts of thinleaf milkwort root-bark, 40-80 parts of grass leaf sweetflag rhizome, 40-80 parts of ginseng, 80-120 parts of tall gastrodia tuber, 80-120 parts of papermulberry fruit, 80-120 parts of ginkgo leaves and 0.01-3 parts of borneol. The traditional Chinese medicine composition can achieve the effects of obviously increasing the number density and surface density of synapse of the molecular layer of mouse hippocampal CA1, obviously enhancing the SOD activities of central cerebral cortex and hippocampus, reducing the content of lipofuscin of the neuron, obviously improving the learning and memory impairment of spontaneous senile dementia model mice, obviously enhancing the activity and fiber density of NOS1 of the central cerebral cortex and hippocampus and obviously up-regulating the contents of SS, AVP and ACTH of the cerebral cortex and hippocampus, especially the content of SS. The traditional Chinese medicine composition can achieve the effect of obviously improving the clinical symptoms of memory and cognitive impairment and has definite curative effects and great application prospects.